• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Rapport Therapeutics Inc.

    3/10/26 7:35:42 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RAPP alert in real time by email
    S-8 1 rapp-20260310.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 10, 2026

    Registration No. 333-

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

    Rapport Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

    Delaware

    88-0724208

    (State or other jurisdiction of
    incorporation or organization)

    (I.R.S. Employer
    Identification No.)

     

    Rapport Therapeutics, Inc.

    99 High Street, Suite 2100

    Boston, MA

    (Address of Principal Executive Offices)

     

    02110

    (Zip Code)

     

    Rapport Therapeutics, Inc. 2024 Stock Option and Incentive Plan
    (Full title of the plan)

    Abraham N. Ceesay, M.B.A.
    Chief Executive Officer
    99 High Street, Suite 2100

    Boston, MA 02110

    (Name and address of agent for service)

     

    (857) 321-8020

    (Telephone number, including area code, of agent for service)

     

    Copies to:
    Kingsley L. Taft
    Stephanie A. Richards

    Goodwin Procter LLP
    100 Northern Avenue
    Boston, Massachusetts 02210
    (617) 570-1000

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


     

    PART I
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    This Registration Statement on Form S-8 (this “Registration Statement”) is being filed by Rapport Therapeutics, Inc. (the “Registrant”) for the purpose of registering 2,388,628 additional shares of common stock, par value $0.001 per share (“Common Stock”), under the Registrant’s 2024 Stock Option and Incentive Plan (the “2024 Plan”), which were added on January 1, 2026 as a result of an automatic annual increase provision therein.

    These additional shares are of the same class as other securities relating to the 2024 Plan for which the Registrant’s registration statement on Form S-8, filed with the Securities and Exchange Commission on June 7, 2024 (File No. 333-280058) and March 11, 2025 (File No. 333-285697), are effective (the “Earlier Registration Statements”).

    Pursuant to General Instruction E to Form S-8 regarding registration of additional securities, the contents of the Earlier Registration Statements, except for “Item 8. Exhibits”, are incorporated herein by reference, except to the extent supplemented, amended or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the Earlier Registration Statements are presented herein.

     

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 8. Exhibits.

    The exhibits to this Registration Statement are listed in the Exhibit Index attached hereto and incorporated by reference herein.

     

    EXHIBIT INDEX

     

     

     

    Exhibit
    No.

     

    Description

     

     

    4.1

     

    Third Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-42121) filed on June 10, 2024).

     

     

    4.2

     

    Form of Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-42121) filed on June 10, 2024).

     

     

    4.3

     

    Amended and Restated Investors’ Rights Agreement, by and between the Registrant and certain of its stockholders, dated as of August 7, 2023 (incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-279486), filed on May 17, 2024).

     

     

    5.1*

     

    Opinion of Goodwin Procter LLP.

     

     

    23.1*

     

    Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.

     

     

    23.2*

     

    Consent of Goodwin Procter LLP (included in Exhibit 5.1).

     

     

    24.1*

     

    Power of Attorney (included on signature page).

     

     

    99.1

     

    Rapport Therapeutics, Inc. 2024 Stock Option and Incentive Plan and form of award agreements thereunder (incorporated by reference to Exhibit 10.2 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-279486) filed on June 3, 2024).

     

     

    107*

    Filing Fee Table.

     

    * Filed herewith.

     


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Massachusetts, on this 10th day of March, 2026.

     

     

     

     

    RAPPORT THERAPEUTICS, INC.

     

     

     

     

     

     

    By:

    /s/ Abraham N. Ceesay

     

     

     

    Name: Abraham N. Ceesay, M.B.A.

     

     

     

    Title: Chief Executive Officer

     

     

     

     

     

    POWER OF ATTORNEY AND SIGNATURES

    Each individual whose signature appears below hereby constitutes and appoints each of Abraham N. Ceesay, M.B.A. and Troy Ignelzi as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

     Signature

     

     Title

     Date

     

     

     

     

    /s/ Abraham N. Ceesay

     

    Chief Executive Officer and Director

    March 10, 2026

    Abraham N. Ceesay, M.B.A.

     

     (Principal Executive Officer)

     

     

     

     

     

    /s/ Troy Ignelzi

     

    Chief Financial Officer

    March 10, 2026

    Troy Ignelzi

     

     (Principal Financial Officer and Principal Accounting Officer)

     

     

     

     

     

    /s/ Steven M. Paul

     

    Director and Chairman

    March 10, 2026

    Steven M. Paul, M.D.

     

     

     

     

     

     

     

    /s/ James I. Healy

     

    Director

    March 10, 2026

    James I. Healy, M.D., Ph.D.

     

     

     

     

     

     

     

    /s/ John Maraganore

     

    Director

    March 10, 2026

    John Maraganore, Ph.D.

     

     

     

     

     

     

     

    /s/ Paul Silva

     

    Director

    March 10, 2026

    Paul Silva

     

     

     

     

     

     

     

    /s/ Raymond Sanchez

     

    Director

    March 10, 2026

    Raymond Sanchez, M.D.

     

     

     

     

     

     

     

    /s/ Robert J. Perez

     

    Director

    March 10, 2026

    Robert J. Perez

     

     

     

     

     

     

     

    /s/ Reid Huber

     

    Director

    March 10, 2026

    Reid Huber, Ph.D.

     

     

     

     

     

     

     

    /s/ Wendy B. Young

     

    Director

    March 10, 2026

    Wendy B. Young, Ph.D.

     

     

     

     

     

     

     

     


    Get the next $RAPP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RAPP

    DatePrice TargetRatingAnalyst
    2/2/2026$43.00Overweight
    Wells Fargo
    11/19/2025$47.00Buy
    BTIG Research
    9/16/2025$44.00Buy
    Truist
    8/6/2025$31.00Buy
    H.C. Wainwright
    4/8/2025Mkt Outperform
    Citizens JMP
    7/2/2024Buy
    TD Cowen
    7/2/2024$35.00Buy
    Jefferies
    7/2/2024$35.00Buy
    Stifel
    More analyst ratings

    $RAPP
    SEC Filings

    View All

    SEC Form S-3ASR filed by Rapport Therapeutics Inc.

    S-3ASR - Rapport Therapeutics, Inc. (0002012593) (Filer)

    3/10/26 8:16:40 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Rapport Therapeutics Inc.

    S-8 - Rapport Therapeutics, Inc. (0002012593) (Filer)

    3/10/26 7:35:42 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Rapport Therapeutics Inc.

    10-K - Rapport Therapeutics, Inc. (0002012593) (Filer)

    3/10/26 7:25:56 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Gault Cheryl sold $58,265 worth of shares (2,014 units at $28.93), decreasing direct ownership by 1% to 169,914 units (SEC Form 4)

    4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

    3/9/26 4:07:30 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Ceesay Abraham sold $320,373 worth of shares (10,916 units at $29.35), decreasing direct ownership by 1% to 556,247 units (SEC Form 4)

    4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

    2/19/26 7:06:29 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Bredt David sold $246,655 worth of shares (8,500 units at $29.02) and exercised 6,000 shares at a strike of $1.80, decreasing direct ownership by 0.63% to 393,075 units (SEC Form 4)

    4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

    2/19/26 7:05:23 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    RAP-219's lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026RAP- 219 epilepsy portfolio expanded with new program in primary generalized tonic-clonic seizures (PGTCS) on strength of Phase 2a FOS dataPhase 2 trial in bipolar mania, development of a long-acting injectable, and other pipeline programs continued to progressEntered into a strategic collaboration and license agreement with Tenacia Biotechnology (Hong Kong) Co., Ltd. to develop and commercialize RAP-219 in Greater China across indications, including focal onset seizures and bipolar maniaEnded the

    3/10/26 7:00:00 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China

    Partnership leverages Tenacia's expertise in central nervous system (CNS) drug development and commercialization to accelerate U.S. and global development of RAP-219 Tenacia obtains exclusive rights to develop and commercialize RAP-219 in Greater China across indications, including focal onset seizures and bipolar mania Rapport to receive upfront cash payment of $20 million, up to $308 million in potential development and commercial milestones and other payments, and mid-single-digit to mid-teens tiered royalties BOSTON and SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport") a clinical-stage biotechnology company dedicated to the discovery

    3/9/26 7:00:00 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rapport Therapeutics to Participate in Upcoming Investor Conferences

    BOSTON and SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today announced that management plans to participate in the following upcoming investor events: TD Cowen 46th Annual Healthcare Conference (Boston, MA) – presentation and fireside chat on Tuesday, March 3, 2026, at 3:10-3:40 pm ET. The Citizens Life Sciences Conference (Miami, FL) – presentation on Tuesday, March 10, 2026, at 2:15 pm ET. Leerink Global Healthcare Conference (Miami, FL) –

    2/24/26 4:05:00 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Huber Reid M bought $499,374 worth of shares (20,400 units at $24.48) (SEC Form 4)

    4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

    9/15/25 4:05:09 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Paul Steven M bought $1,027,111 worth of shares (41,666 units at $24.65) (SEC Form 4)

    4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

    9/15/25 4:05:04 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Young Wendy B. bought $79,100 worth of shares (3,500 units at $22.60), increasing direct ownership by 58% to 9,500 units (SEC Form 4)

    4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

    9/11/25 6:13:48 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Rapport Therapeutics with a new price target

    Wells Fargo initiated coverage of Rapport Therapeutics with a rating of Overweight and set a new price target of $43.00

    2/2/26 6:52:08 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Rapport Therapeutics with a new price target

    BTIG Research initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $47.00

    11/19/25 8:58:22 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Rapport Therapeutics with a new price target

    Truist initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $44.00

    9/16/25 8:09:40 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Rapport Therapeutics Inc.

    SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

    11/14/24 5:13:31 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rapport Therapeutics Inc.

    SC 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)

    11/14/24 3:11:15 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Rapport Therapeutics Inc.

    SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

    11/13/24 12:26:41 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    Leadership Updates

    Live Leadership Updates

    View All

    Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

    Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. "We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. "Ray brings an impress

    8/13/25 8:03:00 AM ET
    $ANRO
    $CERE
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS) disorders Continued momentum in the Phase 2a trial of RAP-219 in patients with refractory focal epilepsy, with topline results expected in the third quarter of 2025Expect to initiate a Phase 2a trial in patients with bipolar mania in the third quarter of 2025, with topline results expected in the first half of 2027  Appointed recognized translational and clinical drug development leader, Jeffrey Sevigny, M.D., as chief medical officer  Ended the year with $305.3 million in cash, cash equivalents, an

    3/11/25 7:00:00 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

    BOSTON and SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced the appointment of Dr. Jeffrey Sevigny as chief medical officer (CMO), effective immediately. A physician-scientist with more than 15 years of leadership in translational and clinical drug development, Dr. Sevigny has spearheaded groundbreaking research across neuroscience and rare diseases. His experience spans the full spectrum of development, from discovery to late-stage clinical trials an

    3/3/25 7:00:00 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    Financials

    Live finance-specific insights

    View All

    Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures

    Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving seizure freedom for the 8-week treatment period (p<0.0001)Data support advancement of RAP-219 into Phase 3 registrational trialsCompany to host a conference call today at 8:00 a.m. ET BOSTON and SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today

    9/8/25 6:00:00 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025

    BOSTON and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will host a conference call and live webcast at 8:00 am ET on September 8, 2025, to report topline results for the Phase 2a trial of RAP-219 in patients with drug-resistant focal onset seizures. Individuals interested in listening to the live conference call may do so through this webcast link or by dialing (800) 715-9871 in the U.S. or (646) 307-1963 for other

    9/5/25 4:05:00 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care